AC607 mesenchymal stromal cells for acute kidney injury in cardiac surgery
Acute Kidney Injury
Enrolment: 156 · Results not recorded
Loading the evidence…
Biologic · ChEMBL NOT QUERIED: plasmid-engineered autologous cell therapy, no chemical or ChEMBL protein entity; resolved=false by entity class. CLASS-LEVEL FLAG: NO human trial administers Nrf2-overexpressing MSC. The 6 recorded trials are UNMODIFIED bone-marrow or adipose MSC in acute kidney injury and ischaemia-reperfusion injury, recorded as the closest translational analogue for the cell platform, not for the Nrf2 modification. NCT06654193 (allogeneic adipose MSC for AKI after trauma or burn) is the only trauma-adjacent entry.
4 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Acute Kidney Injury
Enrolment: 156 · Results not recorded
Acute Kidney Injury
Enrolment: 70 · Results not recorded
Acute Kidney Injury
Enrolment: 24 · Results not recorded
Acute Kidney Injury
Enrolment: 80 · Results not recorded
Kidney Transplantation · Acute Kidney Tubular Necrosis
Enrolment: 120 · Results not recorded
Kidney Transplantation
Enrolment: 120 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Glycerol-induced (rhabdomyolysis) acute kidney injury; 50% glycerol 8 ml/kg injected into the left and right hind femoral muscles after water deprivation
Transplantation of Nrf2-overexpressing mesenchymal stem cells lowered blood urea nitrogen and creatinine and improved kidney regeneration over 14 days, with upregulation of repair markers and downregulation of injury markers, exceeding the effect of unmodified mesenchymal stem cells.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.